
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Bluebird Bio (NASDAQ: BLUE) said its planned acquisition by two investment firms is, according to its board, “in the best interest of stockholders”—but enough of them felt otherwise on Friday to have sent the company’s shares plummeting 42%. The …